Over the last 12 months 5 new peer review papers were published on clinical outcomes of Replicine Functional Keratin wound care products. These included randomized controlled studies of scar healing and donor site healing, as well as a case series study of chronic wounds. These peer review publications are in addition to 9 conference presentations in the same period and consolidate the substantial evidence base supporting clinical use of Replicine Functional Keratin wound care products to manage a wide range of wound types.
Dr Robert Allen Smith, Medical Director of Keraplast Technologies said “Evidence based practice underpins the clinical choices made in wound care. Peer review science is the gold standard for establishing the required evidence base, and as a result of the increasing evidence base for Replicine Functional Keratin, clinicians around the world are embracing keratin as the treatment method of choice.”
Dr Rob Kelly, Chief Scientific Officer of Keraplast Technologies added “The fact that Replicine Functional Keratin wound care products are established in markets around the world with the necessary regulatory approvals and a growing distribution network means that making a good, evidence based decision to manage wounds using keragel, keramatrix or kerasorb, is getting easier and easier. From managing the severe skin disorder epidermolysis bullosa to improving outcomes for chronic wounds, burns, or reducing scars, the clinical decisions being made to use Replicine Functional Keratin are backed by published data.”
The latest publications on Replicine Functional Keratin wound care are listed here: http://www.keraplast.com/evidence-based-wound-care
Keraplast Technologies will be discussing the latest clinical findings on keratin wound care with forward thinking clinicians at the SAWC convention in Orlando, Florida, April 24-26 2014 and the European Wound Management Association (EWMA) conference in Madrid May 14-16 2014